Pharmaceutical ProductCached Profile
ZILVER PTX
Active Ingredients (Generic):Unmapped
Therapeutic Area: Peripheral Intervention
LIFETIME PROMOTIONAL SPEND
$384,616
General Payments Aggregated (2021–2025)
Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.
FDA Patient Safety Profile
Dynamic safety indicators compiled from official FDA product labels.
Active Clinical Trials
Clinical studies listing this drug as an active intervention.
The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery for the Treatment The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery of Femoropopliteal TASC C&D Lesions
UNKNOWNPhase PHASE4NCT01952457
Zilver Paclitaxel(PTX) Thumbwheel Delivery System
COMPLETEDPhase NANCT02271529
Zilver® PTX® Drug-Eluting Peripheral Stent Post-Approval Study
COMPLETEDPhase NANCT01901289
Top Funded Physicians (Cumulative)
Doctors receiving the highest aggregate promotional support for this product.
Dr. MICHAEL WILDERMANMedical Doctor$32,996
Dr. GEORGE ADAMSMedical Doctor$28,582
Dr. CHARLES BAILEYMedical Doctor$23,019
Dr. JOHN PHILLIPSMedical Doctor$15,918
Dr. CONSTANTINO PENAMedical Doctor$15,389
Drug Marketing Payments Log
Federal registry records of promotional speaking, consulting, meals, and offsets.
Year:
2025
2025
2024
2023
2022
2021
Querying Open Payments Database
Fetching live CMS.gov records for ZILVER PTX...